{
    "id": "correct_subsidiary_00122_2",
    "rank": 85,
    "data": {
        "url": "https://www.microtransponder.com/leadership-team",
        "read_more_link": "",
        "language": "en",
        "title": "MicroTransponder",
        "top_image": "https://static.wixstatic.com/media/ef9230_1f6910d8c5ff4a82ac2fb16af5544a7e%7Emv2.png/v1/fit/w_2500,h_1330,al_c/ef9230_1f6910d8c5ff4a82ac2fb16af5544a7e%7Emv2.png",
        "meta_img": "https://static.wixstatic.com/media/ef9230_1f6910d8c5ff4a82ac2fb16af5544a7e%7Emv2.png/v1/fit/w_2500,h_1330,al_c/ef9230_1f6910d8c5ff4a82ac2fb16af5544a7e%7Emv2.png",
        "images": [
            "https://static.wixstatic.com/media/ef9230_1f6910d8c5ff4a82ac2fb16af5544a7e~mv2.png/v1/fill/w_240,h_67,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/LogoWeb.png",
            "https://static.wixstatic.com/media/ef9230_d169e3ef8b8d423f985b6c396686c5bb~mv2.png/v1/crop/x_12,y_10,w_266,h_269/fill/w_123,h_124,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_auto/ManagementTeam-Headshots0_Richard%20Foust-2.png",
            "https://static.wixstatic.com/media/ef9230_b3fe151ed6204c24b112b44b0eaa32cf~mv2.jpg/v1/crop/x_93,y_20,w_256,h_257/fill/w_123,h_123,al_c,q_80,usm_0.66_1.00_0.01,blur_3,enc_auto/NavzerEngineerMDPhD.jpg",
            "https://static.wixstatic.com/media/ef9230_67c9799e4cd24d61ae1028f9b51c5f5f~mv2.jpg/v1/crop/x_74,y_16,w_264,h_264/fill/w_123,h_123,al_c,q_80,usm_0.66_1.00_0.01,blur_3,enc_auto/JordanCurnesMBA.jpg",
            "https://static.wixstatic.com/media/ef9230_e14815cf0ea2483b8b07cb2801d8446d~mv2.png/v1/crop/x_6,y_0,w_277,h_277/fill/w_123,h_123,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_auto/ManagementTeam-Headshots1_7_Doug%20Ellison.png",
            "https://static.wixstatic.com/media/ef9230_b4b912950b09483f9ad72bfa7e821bc1~mv2.jpg/v1/crop/x_80,y_10,w_256,h_257/fill/w_123,h_123,al_c,q_80,usm_0.66_1.00_0.01,blur_3,enc_auto/PrashantRawat.jpg",
            "https://static.wixstatic.com/media/ef9230_2d8e5f6bc9e8481490b1369ad3238785~mv2.jpg/v1/crop/x_77,y_12,w_272,h_272/fill/w_123,h_123,al_c,q_80,usm_0.66_1.00_0.01,blur_3,enc_auto/BunkerCurnes.jpg",
            "https://static.wixstatic.com/media/ef9230_1cb8de4183c84952a6690ac00563d635~mv2.jpg/v1/crop/x_78,y_14,w_272,h_272/fill/w_123,h_123,al_c,q_80,usm_0.66_1.00_0.01,blur_3,enc_auto/MaryKathrynWilliams.jpg",
            "https://static.wixstatic.com/media/ef9230_bfcbeacf1b124415b2f90138a89488bc~mv2.jpg/v1/crop/x_74,y_6,w_272,h_272/fill/w_123,h_123,al_c,q_80,usm_0.66_1.00_0.01,blur_3,enc_auto/BrentTarver.jpg",
            "https://static.wixstatic.com/media/ef9230_3a881607b3954df691707e830ef34271~mv2.jpg/v1/crop/x_70,y_12,w_272,h_272/fill/w_123,h_123,al_c,q_80,usm_0.66_1.00_0.01,blur_3,enc_auto/SpencerBailey.jpg",
            "https://static.wixstatic.com/media/ef9230_d85146779bda49d4a576a67a2bae712d~mv2.png/v1/crop/x_1,y_0,w_285,h_287/fill/w_123,h_124,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_auto/ManagementTeam-Headshots_Philip%20Freed_ed.png",
            "https://static.wixstatic.com/media/ef9230_474cc0a0f5d24aa4a0e293b29665edb7~mv2.png/v1/fill/w_52,h_15,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/LogoWeb2.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "https://static.wixstatic.com/media/ef9230_f7b84c28632f45e6a27557191de0c6fb%7Emv2.png/v1/fill/w_192%2Ch_192%2Clg_1%2Cusm_0.66_1.00_0.01/ef9230_f7b84c28632f45e6a27557191de0c6fb%7Emv2.png",
        "meta_site_name": "MicroTransponder",
        "canonical_link": "https://www.microtransponder.com/leadership-team",
        "text": "Dawson et al. Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial. Lancet. 2021; 397 1545–1553.\n\nMicroTransponder data on file.\n\nPMA P210007\n\nTsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153–e639.\n\nThe Vivistim® Paired VNS™ System (Vivistim) is intended to be used to stimulate the vagus nerve during rehabilitation therapy in order to reduce upper extremity motor deficits and improve motor function in chronic ischemic stroke patients with moderate to severe arm impairment. Do not use if you have had a bilateral or left cervical vagotomy. Risks may include, but are not limited to pain after surgery, hoarseness, bruising, swelling, coughing and throat irritation. While not observed with Vivistim, infection is a risk associated with surgery. For full safety information, please see www.vivistim.com/safety. Individual results may vary."
    }
}